Developer of small-molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat cardio-renal, GI and metabolic diseases. The company through its proprietary drug-development platform has developed a lead product candidate called tenapanor, which has demonstrated an ability to reduce the absorption of dietary sodium and phosphorus, both of which are key factors in the progression of kidney disease.